In 2023, Andrew Guggenhime earned $1.76M in total compensation at Vaxcyte, Inc., including $517.00K salary, $290.81K bonus and $937.58K in stock. Most recently sold 16,000 shares in Jan 2025. Currently holds stock worth $5.56M. 4+ years at the helm of Vaxcyte, Inc..
Compensation History
Annual executive compensation data for Andrew Guggenhime, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$1.76M
Salary
$517.00K
Bonus
$290.81K
Other
$13.00K
Salary
$517.00KBoard Justification
The compensation philosophy aims to attract and retain top talent, align executive compensation with company performance, and ensure competitive pay through peer benchmarking.
Bonus
$290.81KBoard Justification
The annual performance-based bonus earned for 2023 was based on the achievement of corporate performance goals, resulting in a payout of 125% of the target bonus opportunity.
Other Compensation
$13.00KBoard Justification
Other compensation includes life insurance premiums and 401(k) matching contributions.
Restricted Stock
Board Justification
The stock award granted in 2023 that vested includes 22,500 shares of common stock, which vest over a period of time with 1/4 vesting on the six-month anniversary of the grant date and additional shares vesting semi-annually thereafter.
Performance Metrics
The performance metrics for 2023 included achieving corporate goals related to product development and financial objectives.
Andrew Guggenhime
CEO of Vaxcyte, Inc.
Education
B.A. in International Politics and Economics from Middlebury College; M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University
Field of Expertise
Finance & Banking - Finance
Sector of Economy
Healthcare
Born
January 1, 1968 - 57 years ago
CEO of Vaxcyte, Inc. for
4 years 11 months (Jan 2021 - Present)
Previous Experience
Chief Financial Officer at Dermira, Inc., Chief Operating Officer at Dermira, Chief Financial Officer at CardioDx, Inc., Chief Financial Officer at Calistoga Pharmaceuticals, Inc., Senior Vice President and Chief Financial Officer at Facet Biotech Corporation, Chief Financial Officer at PDL BioPharma, Inc.
Holdings
Track Andrew Guggenhime's stock holdings and portfolio value over time.
Total Stock Sold
$17.09M
$17.09M
254,100 PCVX shares
What if they kept their stock?
If Andrew Guggenhime didn't sell their stock, today they would have:
Extra PCVX254,100 shares worth $11.37M.
This is -33.47% and $5.72M less than what they got when they sold the stock.
Insider Trading
Andrew Guggenhime's recent stock transactions, purchases, and sales filed with the SEC.
$1.39M
PCVX at $87.01/share
Jan 21, 2025
Sale
$711.02K
PCVX at $88.88/share
Dec 18, 2024
Sale
$691.02K
PCVX at $86.38/share
Nov 18, 2024
Sale
$4.86M
PCVX at $115.73/share
Oct 18, 2024
Sale
$931.78K
PCVX at $116.47/share
Sep 18, 2024
Sale
$629.53K
PCVX at $78.69/share
Aug 19, 2024
Sale
$653.25K
PCVX at $81.66/share
Jul 18, 2024
Sale
$577.80K
PCVX at $72.22/share
Jun 18, 2024
Sale
$599.42K
PCVX at $74.93/share
May 20, 2024
Sale
$492.58K
PCVX at $61.57/share
Apr 18, 2024
Sale
Rivals
Compare Andrew Guggenhime with competitor CEOs and industry peers.